Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A new paper just published online in Urology suggests that intermittent and testosterone (T)-based LHRH regimens are less likely to be associated with early onset of castration resistance than traditional, continuous, calender-based regimens.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, castration-resistance, LHRH, monotherapy, regimen | 1 Comment »
In Europe, bicalutamide monotherapy with a dose of 150 mg/d is a widely used option for prostate cancer patients who wish to avoid the consequences of standard androgen deprivation using an LHRH agonist such as leuprolide acetate. However, bicalutamide induces gynecomastia (enlargement of the breasts) and mastalgia/mastodynia (pain in the breasts) in most patients.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bicalutamide, monotherapy, pprophylaxis, tamoxifen | 1 Comment »
We have separately addressed data from a 15-year follow-up of a population-based Swedish screening study. Other reports today deal with: The impact of dietary and supplemental zinc on prostate cancer risk Prediction of risk for loss/preservation of erectile function post- prostatectomy Anti-androgen therapy and brachytherapy: options and outcomes
Filed under: Management, Prevention, Risk, Treatment | Tagged: anti-androgen, brachytherapy, diet, erectile function, maximal androgen deprivation, monotherapy, potency, prediction, risk, supplement, surgery, zinc | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site